- Home
- LLY
as 09-15-2025 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 666.0B | IPO Year: | N/A |
| Target Price: | $978.56 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 15.29 | EPS Growth: | 88.31 |
| 52 Week Low/High: | $623.78 - $939.86 | Next Earning Date: | 10-29-2025 |
| Revenue: | $53,258,100,000 | Revenue Growth: | 36.83% |
| Revenue Growth (this year): | 38.43% | Revenue Growth (next year): | 18.06% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zakrowski Donald A | LLY | SVP, Finance, & CAO | Aug 28 '25 | Sell | $734.93 | 1,000 | $734,930.00 | 3,839.659 | |
| Montarce Lucas | LLY | EVP & CFO | Aug 15 '25 | Buy | $691.79 | 715 | $494,626.99 | 14,684.736 | |
| Van Naarden Jacob | LLY | EVP & Pres., Lilly Oncology | Aug 13 '25 | Buy | $647.36 | 1,000 | $647,360.00 | 20,561.985 | |
| Alvarez Ralph | LLY | N/A | Aug 13 '25 | Buy | $660.25 | 758 | $500,472.53 | 758 | |
| Sulzberger Gabrielle | LLY | N/A | Aug 12 '25 | Buy | $641.18 | 234 | $150,036.59 | 2,703.055 | |
| Skovronsky Daniel | LLY | EVP, CSO & Pres. LRL & LLY Imm | Aug 12 '25 | Buy | $634.41 | 2,000 | $1,268,810.00 | 137,660.112 | |
| Fyrwald J Erik | LLY | N/A | Aug 12 '25 | Buy | $642.29 | 3,130 | $2,010,484.70 | 74,577.779 | |
| Ricks David A | LLY | President, Chair, and CEO | Aug 12 '25 | Buy | $644.77 | 3,264 | $2,104,526.02 | 546,601.167 | |
| Yuffa Ilya | LLY | EVP&Pres, LLY USA&Global Capab | Aug 11 '25 | Sell | $627.01 | 2,500 | $1,567,525.00 | 26,259.971 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Insider Monkey
13 hours ago
Eli Lilly and Company (LLY) Unveils AI Platform to Enhance Drug Discovery
GuruFocus.com
13 hours ago
Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly
Simply Wall St.
14 hours ago
Three Stocks Estimated To Be Trading Below Intrinsic Value By Up To 34.7 Percent
MT Newswires
15 hours ago
Market Chatter: Novo Nordisk's Wegovy Delivers Increased Weight Loss in Triple-Dose Trials
Motley Fool
15 hours ago
1 Stock That Should Be in Every Investor's Portfolio
Motley Fool
2 days ago
3 Monster Stocks to Hold for the Next 5 Years
Insider Monkey
2 days ago
Eli Lilly Launches “Brain Health Matters” Campaign with Julianne Moore to Promote Alzheimer’s Disease Awareness
Simply Wall St.
3 days ago
How Investors May Respond To Eli Lilly (LLY) AI Drug Platform Launch and Oncology Breakthroughs
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.